Edwards Lifesciences reported first-quarter results that exceeded Wall Street expectations after market close today. The maker of catheter-delivered heart implants — including transcatheter aortic valve replacement (TAVR) systems and transcatheter mitral and tricuspid therapies (TMTT) — also increased its full-year sales guidance. EW’s stock price was relatively flat in after-hours trading. Irvine, California–based Edwards Lifesciences […]
MassDevice Earnings Roundup
Dexcom stock slides despite Q1 beats, sales guidance increase
Dexcom shares took a hit after hours today on first-quarter results that came in ahead of the consensus forecast on Wall Street. Shares of DXCM dipped about 7% to $128.40 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day […]
ResMed sees increased sleep device demand, stock rises on Q3 beats
ResMed shares ticked up after hours on third-quarter results that came in ahead of the consensus forecast. Shares of RMD rose more than 4% to $191 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day down 1%. The San […]
Integer stock sinks despite Q1 beat as full-year forecast disappoints
Integer stock declined by 10% today despite posting Street-beating first-quarter earnings. Investors were likely reacting to the medtech contract manufacturing giant’s full-year guidance, which was less than the analyst consensus. Plano, Texas–based Integer earned $20.5 million, or 59¢ per share, off of $414.8 million in sales for the quarter ended March 29, 2024. Compared to Q1 […]
Boston Scientific stock is up as Farapulse drives Q1 beat, raised guidance
Boston Scientific shares got a boost this morning on first-quarter results that came in ahead of the consensus forecast. Shares of Boston Scientific ticked up nearly 7% to $73.66 apiece in early-morning trading today. They got as high as $74.39 during the day, marking a 52-week best for the company. MassDevice’s MedTech 100 Index — […]
Intuitive beats the Street in Q1, increases procedure volume forecast
Intuitive Surgical posted first-quarter results today that exceeded the consensus forecast on Wall Street while increasing its forecast for full-year procedure growth. The Sunnyvale, California-based surgical robotics leader reported profits of $545 million, or $1.51 per diluted share, for the three months ended March 31, 2024, up 53% from the first quarter of 2023. Total […]
Abbott increases guidance on strong Q1 results, reports progress on Volt PFA system
Abbott shares fell this today despite first-quarter results that came in ahead of the consensus forecast. Shares of ABT fell more than 3% to $105.81 apiece by later afternoon trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — dipped slightly. The Abbott Park, Illinois-based medtech giant […]
Johnson & Johnson EPS beats The Street in Q1, ups sales guidance
Johnson & Johnson shares dipped slightly today, even as first-quarter earnings came in ahead of the consensus forecast. Shares of JNJ fell 1% to $145.16 apiece by mid-day trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — fell slightly. The New Brunswick, New Jersey-based medtech giant […]
Myomo has a strong outlook for 2024 with new Medicare coverage
Myomo (NYSE:MYO) shares took a hit today on fourth-quarter results that came up short of the consensus forecast. Shares of MYO fell 10% to $3.16 apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — ticked up 0.5%. The Boston-based wearable exoskeleton maker posted […]
Orthofix beats Street in Q4, analysts see positive signs for future
Orthofix Medical are up today on fourth-quarter results that topped the consensus forecast. The Lewisville, Texas–based company posted losses of $22.2 million in the quarter. That equals 59¢ per share on sales of $200.4 million for the three months ended Dec. 31, 2023. The company’s bottom line dipped by more than $15 million further into […]
Vicarious Surgical still expects to submit surgical robot to FDA in 2026
Vicarious Surgical (NYSE:RBOT) management offered an update on the development timeline of its surgical robot as part of its fourth-quarter earnings. Previous expectations earmarked mid-2024 for first-in-human trials and fiscal 2025 for de novo clearance submission. However, CEO Adam Sachs pushed V1.0’s timeline back in November 2023. The company outlined plans for a build and […]